B cell maturation antigen (BCMA)
B lymphocyte stimulator/a proliferation inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B cell maturation antigen immunoglobulin
... the B cell-expressed recep- tors transmembrane activator and CAML interactor (TACI), B cell-maturation antigen (BCMA), and BAFF receptor (BAFF-R), whereas APRIL ...
14
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
... T cell–mediated anti- tumor immunity via multiple potential mechanisms, including reduction of cellular “sinks” leading to increased availability of homeostatic cytokines, and depletion of suppressor cell ...
13
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
... All patients underwent leukapheresis to obtain peripheral blood mononuclear cells from which T cells were purified. CD3 + T cells were transduced with LCAR-B38M lentiviral vector to express anti-BCMA CAR ...
8
Tumor necrosis factor superfamily member APRIL contributes to fibrotic scar formation after spinal cord injury
... and B cell survival and proliferation ...9], B cells, and activated T cells [10] ex- press APRIL, and APRIL can interact with transmem- brane activator and CAML interactor (TACI), B ...
8
Serum BAFF and APRIL levels in patients with IgG4 related disease and their clinical significance
... BAFF: B cell-activating factor of the tumor necrosis factor family; BCMA: B cell maturation antigen; BLys: B-lymphocyte stimulator; CA II: carbonic anhydrase II; ...
8
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
... T cell engagers, and antibody- drug conjugates make the antibody-directed agents more powerful with less ...chimeric antigen receptor (CAR) T cell products. Several CAR-T cell platforms ...
5
Chimeric antigen receptor T cell therapy for multiple myeloma
... T cell therapy against MM. One promising antigen is B cell maturation antigen ...(BCMA). BCMA is expressed in a part of B cells, normal plasma cells, and MM ...
5
Development of targeted adjuvants for HIV-1 vaccines
... for B cell development and differentiation [16, ...on B cells: BAFF receptor (BAFFR), transmembrane activator and calcium modula- tor and cyclophilin ligand interactor (TACI), and B ...
5
Cancer biomarkers for targeted therapy
... T cell engagers, and antibody-drug ...CLL-1, B cell maturation antigen, and CD138 are targets for cancer immunotherapeutic agents, including the chimeric antigen receptor - ...
7
CTLA4Ig inhibits T cell–dependent B cell maturation in murine systemic lupus erythematosus
... IgG-secreting B cells in the spleens of treated mice was markedly affected by CTLA4Ig treat- ...IgG-secreting B cells in the bone marrow was not affected by CTLA4Ig, serum IgG levels in our treated mice may ...
12
B cell receptor revision diminishes the autoreactive B cell response after antigen activation in mice
... the antigen-specific B cells in the spleens of mice immunized with DWEYS-MAP using a fluorochrome- tagged tetrameric peptide (16), we were able to demonstrate RAG expression and l light chain expression in ...
13
The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells
... to maturation and ability to activate human tumor antigen-specific cytotoxic T-cell (CTL) lines, and subsequent T-cell lysis of tumor cells, (b) human regulatory T cells (Tregs), and ...
11
The role of B cell antigen receptors in mantle cell lymphoma
... stem cell transplantation or R-Hyper-CVAD/MA (rituximab with cyclophosphamide, doxorubicin, vincris- tine, dexamethasone, methotrexate, AraC) have a median progression-free survival of more than 7 years ...stem ...
12
Expression of BAFF receptors in muscle tissue of myositis patients with anti Jo 1 or anti Ro52/anti Ro60 autoantibodies
... The authors thank Dr. Maryam Dastmalchi and nurse Christina Ottosson of Karolinska University Hospital for their kind help with muscle biopsy sampling and patient care and Eva Jemseby for handling of the serum biobank, ...
13
The role of BCR destabilization in antigen processing
... that antigen stimulation induces the aggregation of lipid rafts, forming bigger patches of lipid microdomains within the plasma membrane ...for B cell activation (LAB), Lyn or G M1 (Figure ...
123
Toll-like receptors in the pathogenesis of human B cell malignancies
... malignant B-cells upon TLR triggering. Stimulation of TLR9 by CpG in 31 B-cell lymphoma samples strongly induced proliferation in CLL, revealed intermediate effects in MZL, CLL/SLL, FL and DLBCL and ...
10
A unique cell surface antigen identifying lymphoid malignancies of B cell origin
... unique B cell surface differentiation antigen was used to characterize the malignant cells from patients with leukemias or ...B1 antigen. In contrast, tumor cells from T cell leukemias ...
8
Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens Implications for hepatitis B e antigen seroconversion
... hepatitis B surface antigen (HBsAg) ...T cell responses to HBcAg/HBeAg than those of healthy HBsAg carriers (P less than ...T cell responses during acute exacerbations (P less than ...T ...
11
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
... The National Cancer Institute (NCI) investigators for the first time published pre-clinical data on MM treat- ment using anti-BCMA CAR-T cells [9, 10]. Twenty six heavily treated MM patients were enrolled. They ...
9
The Viral Latency-Associated Nuclear Antigen Augments the B-Cell Response to Antigen In Vivo
... The molecular mechanisms by which KSHV latent genes, such as LANA, lead to B-cell hyperplasia, such as MCD, or frank DLBCL, such as PEL, are poorly understood. A number of mechanisms have been proposed for ...
8